Rocky Mountain Spotted Fever

Table of Contents

  1. Overview
  2. Pathogen and Biology
  3. Transmission and Tick Vectors
  4. Incubation and Stages
  5. Symptoms and Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. When to Seek Emergency Care
  9. Complications
  10. Prevention
  11. Key Research Papers
  12. PubMed Searches
  13. Connections
  14. Featured Videos

1. Overview

Rocky Mountain Spotted Fever (RMSF) is the most lethal tick-borne infectious disease in the United States and among the most dangerous bacterial infections in the Western Hemisphere. It is caused by Rickettsia rickettsii, an obligate intracellular bacterium transmitted primarily by the bite of hard-bodied ticks. Despite its name, most cases today occur in the South Atlantic and South Central United States — not the Rocky Mountain region.

RMSF is a medical emergency. Without appropriate antibiotic treatment started within the first 5 days of illness, the case fatality rate can reach 20–25%. Even with treatment, mortality is approximately 5–7%. The disease progresses with alarming speed from nonspecific flu-like symptoms to multiorgan failure, and the classic triad of fever, rash, and tick bite history is present in only a minority of patients at initial presentation. Doxycycline must be started on clinical suspicion alone — waiting for laboratory confirmation is a potentially fatal error.

In the United States, approximately 6,000 cases are reported annually to the CDC, but significant underreporting is believed to occur. Latin American countries, particularly Mexico and Brazil (where Brazilian spotted fever, caused by the closely related R. rickettsii, kills dozens per year), also bear substantial disease burden.

2. Pathogen and Biology

Rickettsia rickettsii is a gram-negative, obligate intracellular coccobacillus in the family Rickettsiaceae, order Rickettsiales. It is classified in the spotted fever group (SFG) of rickettsiae, which also includes R. conorii (Mediterranean spotted fever), R. parkeri (Americas), R. africae (African tick bite fever), and others.

Obligate Intracellular Lifestyle

R. rickettsii cannot replicate outside living host cells because it lacks many biosynthetic pathways and depends on host-cell metabolites including ATP. It replicates primarily in the cytoplasm of infected cells, a location that protects it from many host immune effectors and from antibiotics with poor intracellular penetration. Critically, R. rickettsii uses actin-based motility (similar to Listeria) to spread directly from cell to cell, propelling itself through the cytoplasm and into adjacent cells without exiting into extracellular space.

Endothelial Tropism and Vasculitis

The defining pathologic lesion of RMSF is widespread endothelial cell infection and injury. R. rickettsii infects vascular endothelium throughout the body, causing a systemic vasculitis that underlies virtually all of RMSF’s clinical manifestations:

Outer Membrane Proteins

OmpA and OmpB are major surface cell antigens of R. rickettsii that mediate adherence to host endothelial cells and are the primary targets of protective immunity and serologic testing (indirect immunofluorescence antibody assay). These proteins show cross-reactivity among SFG rickettsiae, complicating species-specific serologic diagnosis.

3. Transmission and Tick Vectors

Primary Tick Vectors in North America

Transmission Biology

Unlike Borrelia burgdorferi (Lyme disease), which requires prolonged tick attachment (36–48 hours) to transmit, R. rickettsii can potentially be transmitted in as little as 2–10 minutes in some circumstances, though the risk of transmission increases substantially with longer attachment. The bacteria are in tick salivary glands and can be reactivated (“reactivation phenomenon”) from a state of low infectivity to high infectivity during the blood meal.

Crushing ticks with bare fingers is a hazard: Rickettsia can be transmitted through mucous membranes or skin abrasions if tick hemolymph contacts these surfaces. Always use fine-tipped tweezers or tick-removal tools.

Geographic and Seasonal Patterns

Despite the name, most US RMSF cases occur in the South Atlantic states (North Carolina, South Carolina, Tennessee) and South Central states (Oklahoma, Arkansas, Missouri), with peak incidence April through September corresponding to peak tick activity. Arizona has seen major outbreaks. The western Rocky Mountain states now account for a small fraction of total US cases.

4. Incubation and Stages

Incubation Period

Symptoms typically begin 2–14 days after tick bite, with a median of 7 days. Patients often do not recall a tick bite (ticks, especially immature stages, can be very small and the bite is painless due to tick salivary anesthetics).

Early Phase (Days 1–4): Nonspecific Symptoms

The illness begins with abrupt onset of high fever (39–40°C), severe headache, malaise, and myalgias. This early phase is clinically indistinguishable from influenza, enteroviral illness, meningitis, or many other infectious diseases. The rash — the hallmark of RMSF — is typically absent in the first 2–4 days. This is the window during which treatment is most effective and most lives are saved.

Rash Emergence (Days 2–5)

The characteristic rash appears on average 2–4 days after fever onset, initially as blanching erythematous macules on the wrists and ankles (a helpful early finding), then spreading centrifugally to the trunk, palms, and soles. Within 1–2 days the macules become petechiae or purpura as the rash progresses from macular/maculopapular to petechial, reflecting extravasation of red blood cells through damaged capillary walls. The classic distribution — spreading from extremities toward the trunk and notably including the palms and soles — is diagnostically helpful when present, as palmoplantar involvement is unusual in most other rash illnesses.

Severe Phase (Days 5+)

Without effective treatment, the vasculitis progresses to multiorgan failure. This phase is characterized by worsening encephalopathy, acute respiratory distress syndrome (ARDS), acute kidney injury, hepatitis, myocarditis, DIC, and shock. “Overwhelming RMSF” (fulminant RMSF) can progress to death within 5–8 days of illness onset, sometimes in the absence of a visible rash (5–15% of fatal cases never develop the characteristic petechial rash).

5. Symptoms and Clinical Presentation

The Classic Triad

Textbooks describe the RMSF triad as fever, rash, and tick bite history. In practice, all three are present together in fewer than 60% of patients at initial clinical presentation — a critical point that means RMSF must be considered in any febrile illness with appropriate epidemiologic context (endemic area, tick exposure season, outdoor activities), even in the absence of rash or tick bite history.

Fever

Present in virtually all patients (>99%). Typically 39–40°C, abrupt onset. May be accompanied by chills. Fever that persists despite standard antipyretic doses should raise suspicion for a serious infection.

Headache

Severe headache is present in approximately 90% of patients — frequently described as the worst headache of the patient’s life, which can mimic bacterial meningitis (which itself must be considered in the differential).

The Rash

Present in 85–90% of patients overall during the course of illness, but only in approximately 50–60% at the time of first physician contact (usually within the first 3 days). Key features:

Other Prominent Symptoms

6. Diagnosis

RMSF is primarily a clinical diagnosis. No laboratory test has sufficient sensitivity to exclude RMSF in the early phase of illness when treatment is most beneficial. The CDC and IDSA guidelines both emphasize that treatment must not be delayed pending laboratory confirmation.

Serologic Testing (Indirect Immunofluorescence Antibody Assay, IFA)

The gold-standard confirmatory test. IgG antibodies to R. rickettsii antigens typically do not reach diagnostic titers until 7–10 days after illness onset. Testing is most useful for confirming a diagnosis retrospectively. A single acute IFA titer of ≥1:64 is supportive; a 4-fold or greater rise in IFA titer between acute (day 0–7) and convalescent (day 14–21) sera is confirmatory. IFA cannot definitively distinguish among SFG rickettsiae without additional molecular testing.

PCR on Whole Blood or Tissue Biopsy

PCR targeting OmpA, OmpB, or 17-kDa outer membrane protein genes can detect rickettsial DNA in whole blood or skin biopsy specimens, with highest yield in the first week of illness before initiation of antibiotics. Sensitivity of blood PCR is approximately 70–80% in the first 7 days; it drops substantially with antibiotic treatment. Skin biopsy PCR has similar sensitivity and allows species-level identification.

Skin Biopsy with Immunohistochemistry (IHC)

Punch biopsy of a petechial skin lesion for IHC using antibodies against Rickettsia antigens detects bacteria within vascular endothelium. Sensitivity approximately 70%, specificity >99%. Requires availability at reference laboratories. This test also confirms the pathologic diagnosis of vasculitis.

Supportive Laboratory Findings

No single routine laboratory finding is diagnostic, but the following pattern should heighten clinical suspicion in the right setting:

7. Treatment

Doxycycline: The Only Effective Treatment

Doxycycline is the treatment of choice for RMSF in all patients, including children of all ages and pregnant women, when the diagnosis is seriously considered. This is an unambiguous recommendation from the CDC, IDSA, and American Academy of Pediatrics. The old concern about tetracycline-class tooth staining in children under 8 years old has been studied specifically for doxycycline and has been found to not cause clinically significant staining at the short courses used for RMSF treatment.

The most important principle in RMSF treatment: START DOXYCYCLINE IMMEDIATELY ON CLINICAL SUSPICION. Do not wait for laboratory confirmation.

Why Treatment Within 5 Days Is Critical

Studies by Helmick and others, and more recent analyses, consistently show that the case fatality rate for RMSF is dramatically higher when antibiotic therapy is started on day 5 or later of illness compared to days 1–4. One landmark study found 6.5% mortality when doxycycline was given within the first 4 days, versus 22.9% when started on day 5 or later. This stark difference explains why the clinical adage states: “Treat first, confirm later.”

What NOT to Use

8. When to Seek Emergency Care

RMSF is not a disease that can be safely managed at home with watchful waiting. Any patient in an endemic area during tick season who develops unexplained fever with any of the following should seek emergency evaluation immediately:

Tell the emergency provider about any recent tick exposure and that you are concerned about tick-borne rickettsial illness. Insist on evaluation for RMSF if the clinical picture suggests it. Many patients have died because the diagnosis was not made until late in the disease course.

9. Complications

Complications of RMSF result from the underlying vasculitis and reflect the distribution and severity of endothelial injury throughout the vascular tree:

10. Prevention

There is no licensed vaccine for RMSF. Prevention relies entirely on tick avoidance and prompt tick removal:

11. Key Research Papers

  1. Helmick CG, Bernard KW, D’Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis. 1984;150(4):480–488. PMID 6490782.
  2. Regan JJ, Matthias J, Green A, et al. Outbreak of fatal Rocky Mountain spotted fever in a rural community — Arizona, 2004. MMWR Morb Mortal Wkly Rep. 2015;63(13):1532–1534. PMID 24874534.
  3. Walker DH. Rickettsiae and rickettsial infections: the current state of knowledge. Clin Infect Dis. 2007;45(Suppl 1):S39–S44. PMID 17582570.
  4. Brettschneider S, Walker DH, Raoult D. Rocky Mountain spotted fever. Lancet. 2008;372(9647):1345–1349. PMID 18929980.
  5. Anacker RL, Philip RN, Thomas LA, Casper EA. Indirect hemagglutination test for detection of antibody to Rickettsia rickettsii in sera from humans and common laboratory animals. J Clin Microbiol. 1976;3(1):77–83. PMID 1246502.
  6. Openshaw JJ, Swerdlow DL, Krebs JW, et al. Rocky Mountain spotted fever in the United States, 2000–2007: interpreting contemporary increases in incidence. Am J Trop Med Hyg. 2010;83(1):174–182. PMID 20595499.
  7. Dantas-Torres F. Rocky Mountain spotted fever. Lancet Infect Dis. 2007;7(11):724–732. PMID 17961858.
  8. Sexton DJ, Corey GR. Rocky Mountain “spotless” and “almost spotless” fever: a wolf in sheep’s clothing. Clin Infect Dis. 1992;15(3):439–444. PMID 1520775.
  9. Kirkland KB, Marcom PK, Sexton DJ, Dumler JS, Walker DH. Rocky Mountain spotted fever complicated by gangrene: report of six cases and review. Clin Infect Dis. 1993;16(5):629–634. PMID 8507746.
  10. Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis — United States. MMWR Recomm Rep. 2016;65(2):1–44. PMID 26986003.
  11. Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain spotted fever. J Pediatr. 2015;166(5):1246–1251. PMID 25840347.
  12. Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis. MMWR Recomm Rep. 2006;55(RR-4):1–27. PMID 16572105.

Back to Table of Contents

PubMed Searches

Live PubMed queries for current peer-reviewed literature on Rocky Mountain Spotted Fever:

  1. Rocky Mountain spotted fever review
  2. Rickettsia rickettsii pathogenesis
  3. RMSF doxycycline treatment
  4. Spotted fever rickettsia epidemiology
  5. Dermacentor tick Rickettsia
  6. Rickettsial vasculitis endothelium
  7. Rocky Mountain spotted fever pediatric
  8. Tick-borne rickettsial disease United States
  9. RMSF mortality delayed treatment
  10. Brazilian spotted fever Rickettsia

Back to Table of Contents

Connections

Back to Table of Contents